Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial.
CONCLUSION: Apatinib combined with S-1 was not superior to other chemotherapy regimens as first-line therapy for advanced gastric cancer. Toxicity was consistent with known profiles when given as monotherapy. There was a tendency toward prolonged mPFS and mOS in patients with lymph node metastasis compared with patients with liver metastasis, which could support the need to design a future clinical trial with a better defined patient population. PMID: 33244809 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 27, 2020 Category: Cancer & Oncology Authors: Zhou N, Zhang C, Liu D, Liu K, Wang G, Zhu H, Zhang J, Jiang M, Liu N, Zhang X Tags: Oncologist Source Type: research

A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in HR-Positive, HER2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.
CONCLUSION: Fulvestrant 500 mg is a feasible and promising hormonal maintenance strategy in ER-positive/HER2-negative advanced breast cancer patients who have no disease progression after first-line chemotherapy. PMID: 33245164 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 27, 2020 Category: Cancer & Oncology Authors: Xu F, Zheng Q, Xia W, Ouyang Q, Pang D, Yuan Z, Shi Y, Peng R, Lu Q, Wang S Tags: Oncologist Source Type: research

Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors.
CONCLUSION: The MTD of SCB01A was 24 mg/m2 every 21 days; it is safe and tolerable in patients with solid tumors. PMID: 33245172 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 27, 2020 Category: Cancer & Oncology Authors: Shiah HS, Chiang NJ, Lin CC, Yen CJ, Tsai HJ, Wu SY, Su WC, Chang KY, Wang CC, Chang JY, Chen LT Tags: Oncologist Source Type: research

Antibiotics and Adverse Events in Pancreatic Cancer Patients Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights.
PMID: 33230870 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 23, 2020 Category: Cancer & Oncology Authors: El Hassouni B, Gregori A, Puik JR, Deng D, Kazemier G, Giovannetti E Tags: Oncologist Source Type: research

Everolimus plus exemestane treatment in metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor therapy.
CONCLUSION: Prior exposure to CDK4/6i therapy did not impact survival outcomes for mHRBC patients taking EVE + EXE. However, there was a trend towards improved OS in the CDK4/6i cohort that should be evaluated in larger cohorts. IMPLICATIONS FOR PRACTICE: The use of CDK4/6 inhibitors in combination with a non-steroidal aromatase inhibitor has become a standard frontline therapy in metastatic hormone receptor-positive breast cancer. An approved subsequent line of therapy is everolimus plus exemestane however the original data supporting this therapy predated prior of approval CDK4/6 inhibitors. As such, the clinical be...
Source: The Oncologist - November 23, 2020 Category: Cancer & Oncology Authors: Cook MM, Rabadi LA, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI Tags: Oncologist Source Type: research

Wild-type APC is associated with poor survival in metastatic microsatellite stable colorectal cancer.
Abstract BACKGROUND: The prognostic implication of wild type APC (APC-WT) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) is not well defined. METHODS: APC prognostic value was evaluated retrospectively in two independent cohorts of patient with MSS mCRC with a confirmatory analysis from a public data set from Memorial Sloan Kettering Cancer Center (MSKCC). RESULTS: In comparison to the APC-mutant (APC-MT) population (n=255), APC-WT patients (n = 86) tended to be younger (59% of age  50), right-sided (41.7% vs. 27%), BRAF-V600E mutated (23.3% vs. 0.8%), and KRAS WT (65...
Source: The Oncologist - November 23, 2020 Category: Cancer & Oncology Authors: Wang C, Ouyang C, Cho M, Ji J, Sandhu J, Goel A, Kahn M, Fakih M Tags: Oncologist Source Type: research

Challenges and opportunities in the management of diffuse large B cell lymphoma in older patients.
Abstract Most patients with diffuse large B-cell lymphoma (DLBCL) are diagnosed at age 60 or over. Challenges to effective therapy among older individuals include unfavorable biologic features of DLBCL, geriatric vulnerabilities, suboptimal treatment selection, and toxicities of cytotoxic chemotherapy. Wider application of geriatric assessments may help identify fit older patients who benefit from standard immunochemotherapy without unnecessary dose reductions. Conversely, attenuated regimens may provide a better balance of risk and benefit for selected unfit or frail patients. Supportive care with the use of cort...
Source: The Oncologist - November 23, 2020 Category: Cancer & Oncology Authors: Di M, Huntington SF, Olszewski AJ Tags: Oncologist Source Type: research

A multicenter analysis of immune checkpoint inhibitors as adjuvant therapy following treatment of isolated brain metastasis.
CONCLUSION: Patients with isolated brain metastases treated with surgery or SRS appeared to benefit from adjuvant ICI, particularly with combination therapy. Recurrences in this setting appear to largely occur intracranially. PMID: 33225544 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 23, 2020 Category: Cancer & Oncology Authors: Patrinely JR, Funck-Brentano E, Nguyen K, Rapisuwon S, Salem JE, Gibney GT, Carlino M, Johnson DB Tags: Oncologist Source Type: research

Efficacy of FOLFOX in patients with aggressive pancreatic NETs after prior capecitabine/temozolomide.
CONCLUSIONS: FOLFOX is active in aggressive, heavily pretreated pNETs who have progressed on prior cap/tem chemotherapy; response durations are relatively short. IMPLICATIONS FOR PRACTICE: FOLFOX chemotherapy has robust activity in patients with aggressively progressive, heavily pretreated pancreatic NETs, a setting where few, if any, other options are likely to be effective. Durations of response, however, are relatively short, and new treatments are urgently needed for patients with aggressive transformation of pancreatic NETs. PMID: 33225478 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 22, 2020 Category: Cancer & Oncology Authors: Al-Toubah T, Morse B, Pelle E, Strosberg J Tags: Oncologist Source Type: research

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
CONCLUSIONS: Thirty-two percent of patients would have been eligible for targeted therapy in CUPISCO. Future studies, including additional biomarkers such as PD-L1 positivity and gLOH, may identify a greater proportion potentially benefiting from CGP-informed treatment. Clinical trial identification number. NCT03498521 IMPLICATIONS FOR PRACTICE: The findings of this retrospective analysis of carcinoma of unknown primary origin (CUP) cases validate the experimental treatment arms being used in the CUPISCO study (NCT03498521), an ongoing randomized trial using comprehensive genomic profiling to assign patients with CUP to ta...
Source: The Oncologist - November 20, 2020 Category: Cancer & Oncology Authors: Ross JS, Sokol ES, Moch H, Mileshkin L, Baciarello G, Losa F, Beringer A, Thomas M, Elvin J, Ngo N, Jin DX, Krämer A Tags: Oncologist Source Type: research

Standardized supportive care documentation improves safety of high-dose methotrexate treatment.
CONCLUSION: The use of standardized documentation for supportive care during HD-MTX therapy is recommended to minimize the risk of adverse events. IMPLICATIONS FOR CLINICAL PRACTICE: High-dose methotrexate (HD-MTX) is a commonly used treatment in several cancer types. Distinct supportive measures are necessary to minimize the risk of HD-MTX side effects, which can be life-threatening. Supportive care consists of certain examinations and interventions prior to starting HD-MTX and permament alkalinization of the urine, as this greatly increases the elimination of MTX and decreases the risk of kidney injury. Here we repo...
Source: The Oncologist - November 20, 2020 Category: Cancer & Oncology Authors: Alsdorf WH, Karagiannis P, Langebrake C, Bokemeyer C, Frenzel C Tags: Oncologist Source Type: research

Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions.
PMID: 33215784 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 20, 2020 Category: Cancer & Oncology Authors: Fang X, Sun Z, Xu-Monette ZY, Young KH Tags: Oncologist Source Type: research

Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer.
CONCLUSIONS: Tumor FSP correlated with prolonged efficacy of anti-PD1 treatment among patients with dMMR cancers, and may represent a new biomarker of immune checkpoint inhibitor sensitivity. IMPLICATIONS FOR PRACTICE: Given the modest efficacy of immune checkpoint inhibition (ICI) in unselected patients with advanced prostate cancer, biomarkers of ICI sensitivity are needed. To facilitate biomarker discovery, we assembled a cohort of patients with DNA mismatch repair-deficient (dMMR) prostate cancer as these patients are enriched for responses to ICI. We observed a high response rate to anti-PD1 therapy in these pati...
Source: The Oncologist - November 20, 2020 Category: Cancer & Oncology Authors: Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, Agarwal N, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES Tags: Oncologist Source Type: research

Patient Navigation to Improve Early Access to Supportive Care for Patients with Advanced Cancer in Resource-limited Settings: a Randomized Controlled Trial.
ontreras-Garduño S, Krush L, Inoyo I, Medina-Campos A, Moreno-García ML, Perez-Montessoro V, Bourlon MT, de la Peña-Lopez R, de la Mora-Molina H, León-Rodriguez E, Mohar A, Goss PE Abstract BACKGROUND: The early integration of supportive care in oncology improves patient-centered outcomes. However, data is lacking regarding how to achieve this in resource-limited settings. We studied whether patient navigation increased access to multidisciplinary supportive care among Mexican patients with advanced cancer. MATERIALS AND METHODS: This randomized controlled trial was conducted betwe...
Source: The Oncologist - November 19, 2020 Category: Cancer & Oncology Authors: Soto-Perez-de-Celis E, Chavarri-Guerra Y, Ramos-Lopez WA, Alcalde-Castro J, Covarrubias-Gomez A, Navarro-Lara Á, Quiroz-Friedman P, Sánchez-Román S, Alcocer-Castillejos N, Aguilar-Velazco JC, Bukowski A, Chávarri-Maldonado JA, Contreras-Garduño S, Kr Tags: Oncologist Source Type: research

A phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08).
CONCLUSIONS: This is the first study reporting on the combination of NUC-1031 with cisplatin in ABC and demonstrated a favourable safety profile; 725mg/m2 NUC-1031 in combination with cisplatin is undergoing phase III trial evaluation in ABC. ClinicalTrials.gov reference: NCT02351765, EudraCT: 2015-000100-26 IMPLICATIONS FOR PRACTICE: The prognosis for patients with advanced biliary tract cancer (ABC) is approximately one year and new treatment options are required. The cisplatin/gemcitabine combination is standard first-line treatment for patients with ABC. NUC-1031 is a phosphoramidate transformation of gemcitabine and i...
Source: The Oncologist - November 19, 2020 Category: Cancer & Oncology Authors: McNamara MG, Bridgewater J, Palmer DH, Faluyi O, Wasan H, Patel A, Ryder WD, Barber S, Gnanaranjan C, Ghazaly E, Evans T, Valle JW Tags: Oncologist Source Type: research

Molecular Profiling of Exceptional Responders to Cancer Therapy.
CONCLUSIONS: The genomic instability detected in our exceptional responders, plus treatment with DNA damage compounds combined with favorable anticancer immunity, may have contributed to exceptional responses to standard anticancer therapies in the patients studied. IMPLICATIONS FOR PRACTICE: With recent advances in the treatment of cancer, there is increased emphasis on the importance of identifying molecular markers to predict treatment response and outcomes, thereby allowing precision oncology. In this study, we hypothesized that there is a "specific biologic signature" in the biology of the cancer in lon...
Source: The Oncologist - November 19, 2020 Category: Cancer & Oncology Authors: Bilusic M, Girardi D, Zhou Y, Jung K, Pei J, Slifker M, Chen Q, Meerzaman D, Alpaugh K, Young D, Flieder D, Gray P, Plimack E Tags: Oncologist Source Type: research

SARS-CoV-2 Clinical Outcomes in Patients with Cancer in a Large Integrated Health Care System in Northern California.
Abstract The SARS-CoV-2 (COVID-19) pandemic continues to affect many lives globally. Patients with cancer undergoing potentially immunosuppressive therapies appear to be at particular risk for the disease and its complications. Here, we describe the experience of patients with cancer within Kaiser Permanente, a large, integrated health system in Northern California. Between February 25, 2020, and June 8, 2020, 4,627 patients were diagnosed with COVID-19, of whom 33 had active cancer treatment within 180 days and 214 had a history of cancer. Patients with active cancer treatment had a statistically higher ri...
Source: The Oncologist - November 18, 2020 Category: Cancer & Oncology Authors: Anantharaman A, Dusendang JR, Schmittdiel JA, Harzstark AL Tags: Oncologist Source Type: research

Cancer in Lockdown: Impact of the COVID-19 Pandemic on Patients with Cancer.
Abstract The lockdown measures of the ongoing COVID-19 pandemic have disengaged patients with cancer from formal health care settings, leading to an increased use of social media platforms to address unmet needs and expectations. Although remote health technologies have addressed some of the medical needs, the emotional and mental well-being of these patients remain underexplored and underreported. We used a validated artificial intelligence framework to conduct a comprehensive real-time analysis of two data sets of 2,469,822 tweets and 21,800 discussions by patients with cancer during this pandemic. Lung and brea...
Source: The Oncologist - November 18, 2020 Category: Cancer & Oncology Authors: Moraliyage H, Silva D, Ranasinghe W, Adikari A, Alahakoon D, Prasad R, Lawrentschuk N, Bolton D Tags: Oncologist Source Type: research

Everolimus-related pneumonitis in metastatic breast cancer patients: Incidence, radiographic patterns and relevance to clinical outcome.
CONCLUSIONS: ERP was noted in half of the MBC patients treated with everolimus. Our data suggested that ERP was associated with improved prognosis and may be used as a biomarker for the efficacy of everolimus in MBC. Close monitoring, prompt diagnosis and proper treatment for ERP are essential to maintain the quality of life of patients and achieve maximum treatment benefits. IMPLICATIONS FOR PRACTICE: Everolimus-related pneumonitis (ERP) is one of the most worrying drug adverse events, especially in Asian patients. However, little has been known about the clinical and radiographic details of ERP in patients with meta...
Source: The Oncologist - November 15, 2020 Category: Cancer & Oncology Authors: Gong C, Xiao Q, Li Y, Gu Y, Zhang J, Wang L, Cao J, Tao Z, Zhao Y, Xie Y, Hu X, Wang B Tags: Oncologist Source Type: research

The Impact of Human Papillomavirus Infection on Skin Cancer: A Population-Based Cohort Study.
CONCLUSIONS: A history of HPV infection is associated with the development of subsequent skin cancer in Taiwanese subjects, and the risk wane 5 years later. IMPLICATIONS FOR PRACTICE: In this Taiwan nationwide cohort study, there was a 2.45-fold increase risk of developing new-onset skin cancers for patients with incident human papillomavirus (HPV) infection, compared with the matched controls. Furthermore, the risk was noticeably significant among aged more than 40 years. A prominent risk of skin cancers was found in group diagnosed with HPV within the first 5 years after index date in this study...
Source: The Oncologist - November 15, 2020 Category: Cancer & Oncology Authors: Chen ML, Wang SH, Wei JC, Yip HT, Hung YM, Chang R Tags: Oncologist Source Type: research

More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment. Oncologist. 2020 Nov 15;: Authors: López-Nieva P, González-Sánchez L, Cobos-Fernández MÁ, Córdoba R, Santos J, Fernández-Piqueras J Abstract The NOTCH1 gene encodes a transmembrane receptor protein with activating mutations observed in many T-cell acute lymphoblastic leukemias (T-ALLs) and lymphomas, as well as in other tumor types, which has led to interest in inhibiting NOTCH1 signaling as a therapeutic target in cancer. Several classes of Notch inhibitors have been develope...
Source: The Oncologist - November 15, 2020 Category: Cancer & Oncology Authors: López-Nieva P, González-Sánchez L, Cobos-Fernández MÁ, Córdoba R, Santos J, Fernández-Piqueras J Tags: Oncologist Source Type: research

Extended RAS Analysis of the Phase 3 EPIC Trial: Irinotecan + Cetuximab vs Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
CONCLUSION: PFS, ORR, and QoL were improved with cetuximab plus irinotecan as a second-line treatment in patients with RAS-wt mCRC, confirming that cetuximab-based therapy is suitable in this population. Almost half of patients in the irinotecan arm received post-study cetuximab, masking a potential OS benefit of cetuximab addition. IMPLICATIONS FOR PRACTICE: Cetuximab is approved for the treatment of RAS-wild-type metastatic colorectal cancer (mCRC). In this retrospective analysis of the phase 3 EPIC study (cetuximab plus irinotecan versus irinotecan alone as second-line treatment in patients with RAS-unselected mCRC...
Source: The Oncologist - November 15, 2020 Category: Cancer & Oncology Authors: Sobrero A, Lenz HJ, Eng C, Scheithauer W, Middleton G, Chen W, Esser R, Nippgen J, Burris H Tags: Oncologist Source Type: research

The EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Pignatti F Abstract On August 25, 2020, a marketing authorization valid through the European Union was issued for belantamab mafodotin monotherapy for the treatment of multiple myeloma (MM) in adult patients who have received at least four prior therapies, whose disease is refractory to at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody (mAb), and who have demonstrated disease progression on the last therapy. Belantamab mafodotin is an antibody-drug conjugate that combines a mAb, which binds specifically to B-cell maturation antigen, with maleimidocapro...
Source: The Oncologist - November 11, 2020 Category: Cancer & Oncology Authors: Tzogani K, Penttilä K, Lähteenvuo J, Lapveteläinen T, Lopez Anglada L, Prieto C, Garcia-Ochoa B, Enzmann H, Gisselbrecht C, Delgado J, Pignatti F Tags: Oncologist Source Type: research

2020 Innovation Based Optimism for Lung Cancer Outcomes.
Abstract Lung cancer is the leading cause of cancer death in both males and females in the US and worldwide. Due to advances in prevention, screening/early detection and therapy. Lung cancer mortality rates are decreasing and survival rates are increasing. These innovations are basic on scientific discoveries in imaging, diagnostics, genomics, molecular therapy and immunotherapy. Outcomes have improved in all histologies and stages. This review provides information on the clinical implications of these innovations that are practical for the practicing physicians, especially oncologists of all specialities who diag...
Source: The Oncologist - November 11, 2020 Category: Cancer & Oncology Authors: Schenk EL, Patil T, Pacheco J, Bunn PA Tags: Oncologist Source Type: research

Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors; more common than we thought.
PMID: 33150991 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 5, 2020 Category: Cancer & Oncology Authors: Salinas C, Samtani S, Burotto M Tags: Oncologist Source Type: research

Response to: Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors; more common than we thought.
PMID: 33150998 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 5, 2020 Category: Cancer & Oncology Authors: Gubbi S, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL, Del Rivero J Tags: Oncologist Source Type: research

COVID-19 Pandemic and Cancer: The Importance of Early Palliative Care.
PMID: 33150691 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 4, 2020 Category: Cancer & Oncology Authors: Potenza L, Luppi M, Efficace F, Bruera E, Bandieri E Tags: Oncologist Source Type: research

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutated -Metastatic Castrate Resistant Prostate Cancer.
This article summarizes the FDA thought process and data supporting this accelerated approval. IMPLICATIONS FOR PRACTICE: The accelerated approval of rucaparib for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated mCRPC who have been treated with androgen receptor-directed therapy and a taxane represents the first approved therapy for this selected patient population. This approval was based on a single-arm trial demonstrating a confirmed objective response rate greater than that of available therapy with a favorable duration of response and an acceptable toxicity profile. ...
Source: The Oncologist - November 4, 2020 Category: Cancer & Oncology Authors: Anscher MS, Chang E, Gao X, Gong Y, Weinstock C, Bloomquist E, Adeniyi O, Charlab R, Zimmerman S, Serlemitsos-Day M, Ning YM, Mayrosh R, Fuller B, Trentacosti AM, Gallagher P, Bijwaard K, Fahnbulleh F, Diggs F, Arora S, Goldberg KB, Tang S, Amiri-Kordesta Tags: Oncologist Source Type: research

Navigating diagnostic and treatment decisions in non-small-cell lung cancer: expert commentary on the multidisciplinary team approach.
Abstract Non-small cell lung cancer (NSCLC) accounts for approximately one in five cancer-related deaths and management requires increasingly complex decision-making by healthcare professionals. Many centers have therefore adopted a multidisciplinary approach to patient care, using the expertise of various specialists to provide the best evidence-based, personalized treatment. However, increasingly complex disease staging, as well as expanded biomarker testing and multi-modality management algorithms with novel therapeutics, have driven the need for multifaceted, collaborative decision-making to optimally guide th...
Source: The Oncologist - November 3, 2020 Category: Cancer & Oncology Authors: Popat S, Navani N, Kerr KM, Smit EF, Batchelor TJP, Van Schil P, Senan S, McDonald F Tags: Oncologist Source Type: research

A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.
CONCLUSION: Our data showed that PHY906 increases the therapeutic index of capecitabine by enhancing its antitumor activity and reduces its toxicity profile in advanced HCC. PMID: 33140457 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 3, 2020 Category: Cancer & Oncology Authors: Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y Tags: Oncologist Source Type: research

A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer.
CONCLUSION: We did not observe a higher proportion of patients undergoing breast conservation surgery in the eribulin group than in the paclitaxel group. The patients treated with eribulin were more likely to undergo mastectomy and less likely to undergo breast conservation surgery, but the difference was not statistically significant. As neoadjuvant therapy for operable HER2-negative breast cancer, eribulin followed by FAC/FEC is not superior to paclitaxel followed by FAC/FEC and is associated with a higher incidence of neutropenia-related serious AEs. PMID: 33140515 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 3, 2020 Category: Cancer & Oncology Authors: Lim B, Song J, Ibrahim NK, Koenig KB, Chavez-MacGregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V Tags: Oncologist Source Type: research

A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
CONCLUSION: The combination of enobosarm and pembrolizumab was well tolerated with a modest clinical benefit rate of 25% at 16 weeks in heavily pretreated AR+ TNBC without pre-selected PD-L1. Future clinical trials combining AR targeted therapy with immune checkpoint inhibitor (ICI) for AR+ TNBC warrant investigation. PMID: 33141975 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - November 3, 2020 Category: Cancer & Oncology Authors: Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Gillece JD, Folkerts M, Reining L, Highlander SK, Robinson K, Padam S, Martinez N, Tang A, Schmolze D, Waisman J, Sedrak M, Lee PP, Mortimer J Tags: Oncologist Source Type: research

Erdheim-Chester Disease and Langerhans cell histiocytosis: a case of overlap-syndrome.
PMID: 33111453 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - October 28, 2020 Category: Cancer & Oncology Authors: Ippolito D, Ragusi M, Maino C, Pecorelli A, Giandola T, Franzesi CT, Sironi S Tags: Oncologist Source Type: research

Dramatic changes in oncology care pathways during the COVID-19 pandemic: The French ONCOCARE-COV study.
te; O Abstract The coronavirus disease 2019 (COVID-19) pandemic may have affected cancer management. We aimed to evaluate changes in every oncology care pathway essential steps, from screening to treatment during the pandemic. Monthly oncological activity differences between 2019 and 2020 (screening tests, histopathological analyzes, multidisciplinary tumor board meetings (MTMB), diagnostic announcement procedures (DAP), and treatments) were calculated in two French areas experiencing different pandemic's intensity (Reims and Colmar). COVID-19 has had a dramatic impact in terms of screening (-86% to -100%), diagno...
Source: The Oncologist - October 28, 2020 Category: Cancer & Oncology Authors: Brugel M, Carlier C, Essner C, Debreuve-Theresette A, Beck MF, Merrouche Y, Bouché O Tags: Oncologist Source Type: research

Multicenter comparison of Molecular Tumor Boards in the Netherlands: definition, composition, methods and targeted therapy recommendations.
CONCLUSION: MTBs associated with tertiary cancer referral centers in the Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a "Dutch MTB model" for an optimal, collaborative and nationally aligned MTB workflow. IMPLICATIONS FOR PRACTICE: Interpretation of genomic analyses for optimal choice of target therapy for cancer patients is becoming increasingly complex. A Molecular Tumor Board (MTB) supports oncologist to rationalize therapy options. However, there is no consensus on the most optimal setup for an MTB which can affe...
Source: The Oncologist - October 28, 2020 Category: Cancer & Oncology Authors: Koopman B, Groen HJM, Ligtenberg MJL, Grünberg K, Monkhorst K, de Langen AJ, Boelens MC, Paats MS, von der Thüsen JH, Dinjens WNM, Solleveld N, van Wezel T, Gelderblom H, Hendriks LE, Speel EJM, Theunissen TE, Kroeze LI, Mehra N, Piet B, van der Wekken Tags: Oncologist Source Type: research

Emerging Immunotherapies in the Treatment of Brain Metastases.
Abstract Brain metastases account for considerable morbidity and mortality in cancer patients. Despite increasing prevalence, limited therapeutic options exist. Recent advances in our understanding of the molecular and cellular underpinnings of the tumor immune microenvironment and the immune evasive mechanisms employed by tumor cells has shed light on how immunotherapies may provide therapeutic benefit to patients. The development and evolution of immunotherapy continues to show promise for the treatment of brain metastases. Positive outcomes have been observed in several studies evaluating the efficacy and safet...
Source: The Oncologist - October 26, 2020 Category: Cancer & Oncology Authors: Nieblas-Bedolla E, Nayyar N, Singh M, Sullivan RJ, Brastianos PK Tags: Oncologist Source Type: research

A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors.
CONCLUSION: Ipilimumab was well tolerated in Chinese patients, showing similar safety and PK to previous studies in predominantly Caucasian populations. PMID: 33105036 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - October 26, 2020 Category: Cancer & Oncology Authors: Sheng J, Zhang L, Ma Y, Fang W, Zhao H, Bathena SP, Tendolkar A Tags: Oncologist Source Type: research

A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients with Advanced Solid Malignancies.
CONCLUSION: Despite having an attractive safety profile, hVEGF26-104 /RFASE was not able to elicit seroconversions against native hVEGF165 and, consequently, did not decrease circulating VEGF levels. Deficient RFASE adjuvant activity, as well as dominant immunoreactivity towards neo-epitopes, may have impeded hVEGF26-104 /RFASE's efficacy in man. PMID: 33105058 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - October 26, 2020 Category: Cancer & Oncology Authors: Goedegebuure RSA, Wentink MQ, van der Vliet HJ, Timmerman P, Griffioen AW, de Gruijl TD, Verheul HMW Tags: Oncologist Source Type: research

Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple Negative Breast Cancer.
Abstract BACKGROUND: In this phase II clinical trial, we evaluated the efficacy of the non-anthracycline combination of carboplatin and nab-paclitaxel in early stage triple negative breast cancer (TNBC). PATIENTS AND METHODS: Patients with newly diagnosed stage II-III TNBC (N=69) were treated with neoadjuvant carboplatin (AUC 6) every 28 days x 4 plus nab-paclitaxel (100 mg/m2 ) weekly for 16 weeks. Pathological complete response (pCR) and residual cancer burden (RCB) were analyzed with germline mutation status, tumor infiltrating lymphocytes (TILs), TNBC molecular subtype, and GeparSixto immune...
Source: The Oncologist - October 24, 2020 Category: Cancer & Oncology Authors: Yuan Y, Lee JS, Yost SE, Li SM, Frankel PH, Ruel C, Schmolze D, Robinson K, Tang A, Martinez N, Stewart D, Waisman J, Kruper L, Jones V, Menicucci A, Uygun S, Yoder E, van der Baan B, Yim JH, Yeon C, Somlo G, Mortimer J Tags: Oncologist Source Type: research

Paclitaxel-Carboplatin Doublets-More Finer Points to Learn.
PMID: 33098242 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - October 24, 2020 Category: Cancer & Oncology Authors: Muggia F Tags: Oncologist Source Type: research

Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation.
CONCLUSION: The majority of patients having regret were identified early using the PRO 3-IGI of the eLCSS-QL measure. Identifying patients at risk for regret allows for interventions, including frank discussions of progress and goals early in the treatment course, which could address regret in patients and their supporters. IMPLICATIONS FOR PRACTICE: This report documents prospectively for the first time the incidence of treatment-related regret in patients with advanced lung cancer, and outlines that risk of regret is associated with patient-determined worsening health status early in the course of treatment. Identif...
Source: The Oncologist - October 23, 2020 Category: Cancer & Oncology Authors: Hollen PJ, Gralla RJ, Gentzler RD, Hall RD, Coyne B, Cheng H, Halmos B, Gildersleeve J, Calderon C, Hinton I, Weiss G, Crawford J, Cerise J, Lesser M Tags: Oncologist Source Type: research

The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
CONCLUSION: This study illustrates the circulating and tumor genomic profile in the largest HNSCC cohort to date, underscoring the potential utility of ctDNA in prognostication and precision oncology treatment. For the first time, the presence of ctDNA alterations and specific ctDNA sequencing results were shown to be significantly associated with poor prognosis in HNSCC. IMPLICATIONS FOR PRACTICE: The use of precision genomic targeted therapies in Head and Neck Squamous Cell Carcinoma (HNSCC) lags behind many other cancers and poor survival in advanced stages indicates the urgent need for improved treatment options. ...
Source: The Oncologist - October 23, 2020 Category: Cancer & Oncology Authors: Wilson HL, D'Agostino RB, Meegalla N, Petro R, Commander S, Topaloglu U, Zhang W, Porosnicu M Tags: Oncologist Source Type: research

Providing Supportive and Palliative Care Using Telemedicine for Patients with Advanced Cancer During the COVID-19 Pandemic in Mexico.
We report the results of a multidisciplinary patient-navigator-led telemedicine supportive care program in Mexico City. One-hundred sixty-three telemedicine interventions were provided to 45 patients (median age 68, 57% female). A quarter of the patients had less than or equal to elementary school education, and 15% lived in a rural area. The most common interventions were psychological care (33%), pain and symptom control (25%), and nutritional counseling (13%). Half of the interventions were provided by video conferencing. The most common patient-reported barrier was limited experience using communication technology (). ...
Source: The Oncologist - October 22, 2020 Category: Cancer & Oncology Authors: Chávarri-Guerra Y, Ramos-López WA, Covarrubias-Gómez A, Sánchez-Román S, Quiroz-Friedman P, Alcocer-Castillejos N, Del Pilar Milke-García M, Carrillo-Soto M, Morales-Alfaro A, Medina-Palma M, Aguilar-Velazco JC, Morales-Barba K, Razcon-Echegaray A, Tags: Oncologist Source Type: research

Breast Cancer-Specific Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study.
CONCLUSION: Patients with stage IV cancer with small-sized tumors may have BCSM as high as those with larger tumors. In TNBCs, very small tumors with severe LN involvement are associated with the worst BCSM. Continued efforts are needed to further investigate Ta1/T1bN2 + M1 TNBCs and individualize the treatment for affected patients. IMPLICATIONS FOR PRACTICE: This study revealed that for stage IV breast cancer, smaller primary tumors were not always associated with better breast cancer-specific mortality. This study illustrated that very small triple-negative breast cancers (TNBCs) with extensive regional l...
Source: The Oncologist - October 19, 2020 Category: Cancer & Oncology Authors: Zheng YZ, Wang XM, Fan L, Shao ZM Tags: Oncologist Source Type: research

The impact of the COVID-19 pandemic on surgical management of breast cancer: global trends and future perspectives.
PMID: 33044007 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - October 12, 2020 Category: Cancer & Oncology Authors: Rocco N, Montagna G, di Micco R, Benson J, Criscitiello C, Chen L, Di Pace B, Colmenarejo AJE, Harder Y, Karakatsanis A, Maglia A, Mele M, Nafissi N, Ferreira PS, Taher W, Tejerina A, Vinci A, Nava M, Catanuto G Tags: Oncologist Source Type: research

In Reply: Correlation between Bevacizumab Exposure and Survival does not necessarily imply Causality. Letter to the Editor.
PMID: 33044037 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - October 12, 2020 Category: Cancer & Oncology Authors: Papachristos A, Kemos P, Kalofonos H, Sivolapenko G Tags: Oncologist Source Type: research

Prognostic clinical and radiographic biomarkers for BRAF targeted therapy in advanced melanoma.
Abstract Agents blocking BRAF and MEK produce robust responses in patients with BRAFV600 mutated melanoma, however more accurate clinical biomarkers are needed to predict prognosis. To explore this question, we retrospectively studied 158 patients with BRAF-mutated melanoma treated with BRAF +/- MEK inhibitors. We found that the number of distinct tumor sites upon initiation of targeted therapy is associated with decreased progression-free survival but had no effect on overall survival. Serum values of LDH and ALC/ANC ratio independently had the strongest association with both progression-free survival and overall...
Source: The Oncologist - October 12, 2020 Category: Cancer & Oncology Authors: Shah KP, Song H, Ye F, Johnson DB Tags: Oncologist Source Type: research

Correlation between Bevacizumab Exposure and Survival does not necessarily imply Causality. Letter to the Editor.
PMID: 33044752 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - October 12, 2020 Category: Cancer & Oncology Authors: Le Louedec F, Chatelut E Tags: Oncologist Source Type: research

To transplant or not to transplant during the SARS COV 2 pandemic? That is the question.
Abstract The novel coronavirus disease 2019 has grown to be a global public-health emergency. The rapid spread of the infection, have raised many questions in the oncohematological scientific community regarding the appropriateness of high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT). We here report two cases of patients who received ASCT at our Institute during the epidemic in Italy, respectively affected with Hodgkin lymphoma and germ cell tumour. The two patients underwent a nasopharyngeal Swab for Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV2) on hospital admittanc...
Source: The Oncologist - October 12, 2020 Category: Cancer & Oncology Authors: Marino D, Finotto S, Basso U, Galiano A, Bolshinsky M, Amato O, Marson P, Tison T, Colpo A, Zagonel V Tags: Oncologist Source Type: research

Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
CONCLUSION: The poor overall outcomes observed in this study may give clinicians pause when considering ICI therapy for hospitalized patients, particularly those with characteristics that are associated with a greater risk of mortality. IMPLICATIONS FOR PRACTICE: Immunotherapy strategies for cancer patients are rapidly evolving and their use is expanding, but not all patients will develop a response, and secondary toxicity can be significant and challenging. This is especially evident on hospitalized patients, where the economic cost derived from inpatient ICI administration is important and the clinical benefit is so...
Source: The Oncologist - October 12, 2020 Category: Cancer & Oncology Authors: Durbin SM, Zubiri L, Niemierko A, Bardia A, Sullivan RJ, McEwen C, Mulvey TM, Allen IM, Lawrence DP, Cohen JV, Hochberg EP, Ryan DP, Petrillo LA, Reynolds KL Tags: Oncologist Source Type: research